TMCnet News

Research and Markets: Asia Pacific Insulin Market Review to 2018 - Transition from Human Insulin to Analog Insulin
[December 16, 2014]

Research and Markets: Asia Pacific Insulin Market Review to 2018 - Transition from Human Insulin to Analog Insulin


Research and Markets (http://www.researchandmarkets.com/research/xbzmj7/asia_pacific) has announced the addition of the "Asia Pacific Insulin Market Review to 2018 - Transition from Human Insulin to Analog Insulin" report to their offering.

The industry research publication titled Asia Pacific Insulin Market Review to 2018 - Transition from Human Insulin to Analog Insulin' presents a comprehensive analysis of market size by value of major types of insuln consumed in Asia Pacific region. The report entails the market share analysis of major insulin brands in premix insulin, long acting and rapid acting insulin category and company profiles of major players in the insulin market in India, China and Japan. The future analysis has also been discussed in each market.



Key Topics Covered:

1. Asia Pacific Insulin Market Introduction


2. India Insulin Market Introduction

3. China Insulin Market Introduction

4. Japan Insulin Market Introduction

5. Appendix

Companies Mentioned

  • BJ Ganli Pharmaceuticals
  • Biocon Limited
  • Eli Lilly and Company
  • Eli Lilly and Company India Private Limited
  • Novo Nordisk (China) Pharmaceutical Company Limited
  • Novo Nordisk India Private Limited
  • Sanofi China
  • Sanofi India Limited
  • Wockhardt Limited

For more information visit http://www.researchandmarkets.com/research/xbzmj7/asia_pacific


[ Back To TMCnet.com's Homepage ]